Cleerly

Cardiovascular disease (CVD) is still the #1 cause of death, yet today’s standard of care remains reactive, not proactive. ?? Over 50% of heart attacks occur in asymptomatic patients. ?? CVD costs are projected to hit $2 trillion by 2050. At Cleerly, we believe early detection and prevention are the key to reducing heart attacks, saving lives, and easing the burden on our healthcare system. Over a decade of research confirms the type of atherosclerotic plaque—not just risk factors—matter most. Our AI-powered advanced plaque analysis delivers precise, personalized insights, shifting cardiac care from late-stage intervention to true prevention. It's time to rethink cardiac care. Learn more here: https://lnkd.in/gfjBrhcg #YesCCT #CCTA #Cardiology #CardiacCare #DigitalHealth

Community first! ??? Before ACC.25 officially begins, we’re hitting the ground in Chicago a little early for some heart-healthy education. On March 25, we’re proud to support the American College of Cardiology at the Chicago Community Health Fair—an event dedicated to raising awareness about heart disease risk factors and educating the community with actionable strategies for improving heart health. Alongside Johnson & Johnson and Amgen, we're joining local healthcare leaders to empower Chicago with knowledge that can lead to a healthier future. Learn more here: https://lnkd.in/gwgEgEAR #ACC #ACC25 #HeartHealth #HeartDisease #Community #CardioSmart #HealthFair

?? According to the American Heart Association, nearly 45% of women aged 20 and older are living with some form of cardiovascular disease. ?? Our latest webinar offers a scientific overview of the benefits of coronary CTA and AI-powered plaque analysis in accurately assessing the risk of coronary artery disease in women. Join Dr. Fatima Rodriguez, MD, MPH, as she shares clinically supported insights on how understanding female-specific cardiovascular risk factors can enhance prevention and treatment strategies. Watch now and get the latest insights: https://lnkd.in/g_6PgGXG #YesCCT #CCT #Hearthealth #HeartDisease #DigitalHealth #MedTech #AIinHealthcare #AIQCT

It's time to move beyond risk factors and measure true heart health. ???? Cleerly’s AI-powered advanced plaque analysis characterizes and quantifies atherosclerosis—the root cause of heart disease. With comprehensive data on the type and amount of plaque present, healthcare professionals can more accurately assess a patient’s risk for coronary artery disease. ?? Learn more here: https://lnkd.in/g2cXZf34 #YesCCT #CCTA #CardiacImaging #ArterialPlaque #Cardiology #HeartDisease #Atherosclerosis

We love to celebrate our team! ???? Happy Employee Appreciation Day to every Cleerly employee! Your passion, dedication, and innovation are truly at the heart of our mission. You are the dreamers, innovators, and changemakers dedicated to raising the standard of cardiac care and improving patient outcomes. Because of you, we're empowering healthcare professionals with AI-driven, non-invasive tools to diagnose and manage heart disease with greater precision. We're honored to be on this journey together! ?? #EmployeeAppreciationDay #ThankYou #ThankYouTeam #EmployeeRecognition

If you haven't heard of AI-QCT, now's the time! A study utilizing Cleerly's AI-driven plaque analysis has been recognized as one of the Top 10 papers in Ischaemic Heart Disease by the European Heart Journal! ???? A huge shoutout to our research fellow in Amsterdam, Dr. Nick Nurmohamed, and the entire team for their dedication to advancing heart disease risk assessment. This work highlights how AI-powered CCTA (AI-QCT) analysis may enhance risk assessment, bringing us closer to a future where cardiac care is proactive, precise, and personalized. Curious to read the paper? Check it out here: https://lnkd.in/gZvbn83P #Cleerly #Cardiology #ResearchExcellence #HeartHealth #YesCCT #CCTA #ClinicalEvidence

Old scan ?? new insights You read that right, Cleerly can analyze most older CCTAs, giving healthcare professionals (HCPs) fast, AI-powered insights to characterize and quantify atherosclerosis. This means HCPs can analyze past scans to gain a deeper understanding of patient’s heart health—without the need for a new scan. Turn past scans into powerful insights. ?? Learn more here: https://lnkd.in/gfjBrhcg #YesCCT #CCTA #CardiacImaging #DigitalHealth #CTFirst

?? Exciting News! ?? We’re thrilled to announce our partnership with Bunkerhill Health to revolutionize early disease detection and risk assessment for coronary artery disease. Together, we’re integrating cutting-edge, FDA-cleared AI technologies to ensure at-risk patients receive timely care when they need it most. This collaboration will empower health systems to identify and analyze cardiovascular risks with unmatched precision, paving the way for better patient outcomes and proactive care. With patients at the center of our partnership, we believe we can effectively combat the number one killer and move toward a future where cardiac care is precise, proactive, and capable of preventing heart attacks. ?? Read the full press release here: https://lnkd.in/gZWTpYSq #DigitalHealth #MedTech #AIinHealthcare #Cardiology #YesCCT #AI #HealthcareInnovation

Detecting significant stenosis early can be tough; many traditional methods leave gaps, leading to delayed diagnoses and unnecessary downstream procedures. Here's where Cleerly steps in. ???? With 95% sensitivity for detecting ≥50% stenosis, Cleerly's AI-powered analysis offers a more reliable, efficient solution compared to Stress Tests' 74% sensitivity. Adding CCTA with Cleerly’s advanced plaque analysis to your workflow can help reduce missed diagnoses and improve your practice's diagnostic performance in detecting obstructive CAD. ? ?? Ready to take the next step in revolutionizing your practice? https://lnkd.in/g7D-4dDa Source: https://lnkd.in/gxHi37Sz #ClinicalEvidence #YesCCT #CCTA #CTFirst #HeartDisease #Stenosis #DigitalHealth

Heart Month may be ending, but the mission to transform cardiac care continues. ???? As Heart Month draws to a close, we want to remind you that our dedication to improving the standard of care continues. At Cleerly, we believe in a future where patients receive proactive, precise care and healthcare professionals are empowered with the best tools and insights to make confident, data-driven decisions. Our team is committed to expanding partnerships, advocating for greater coverage, and supporting groundbreaking clinical trials to make non-invasive AI-powered coronary CTA analysis more accessible. Join us in shaping the future of coronary artery disease management for a healthier tomorrow! ??? #HeartMonth #HeartHealth #YesCCT #CCTA #MedTech